Table 1

Baseline clinical characteristics of the study population

All (n=87)follow-up (+) (n=61)Follow-up (−) (n=26)P value
Follow-up
(+) vs (−)
Age, years58±1458±1458±120.88
Female, n (%)55 (63)36 (59)19 (73)0.22
Body surface area, m2 1.6±0.21.6±0.21.5±0.20.28
Haemoglobin, g/dL11.8±2.211.7±2.212.1±2.40.48
Creatinine, g/mL0.72±0.220.73±0.240.70±0.150.53
Medications
 ACE inhibitor or ARB, n (%)12 (14)7 (11)5 (19)0.34
 Beta-blocker1 (1)1 (1.6)0 (0)
Background diseases
 Breast cancer, n (%)38 (44)25 (41)13 (50)0.44
 Malignant lymphoma, n (%)35 (40)27 (44)8 (31)0.24
 Others, n (%)14 (16)9 (15)5 (19)0.61
Smoking history, n (%)26 (30)20 (33)6 (23)0.37
Hypertension, n (%)30 (34)21 (34)9 (35)0.98
Diabetes mellitus, n (%)8 (9)4 (7)4 (15)0.19
Hyperlipidaemia, n (%)12 (14)8 (13)4 (15)0.78
Anthracycline chemotherapy
 Epirubicin, n (%)40 (46)25 (41)15 (58)0.44
 Average dose, mg/m2 264±126282±104250±1770.50
 Doxorubicin, n (%)37 (43)25 (41)12 (46)0.66
 Average dose, mg/m2 153±108152±85167±1270.84
 Others16 (18)10 (16)6 (23)0.46
Trastuzumab, n (%)16 (18)11 (18)5 (19)0.92
  • Values are n (%) or mean±SD.

  • ARB, angiotensin II receptor blocker1.